Literature DB >> 15482489

Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.

Christopher J Miller, Mitchell Cheung, Arati Sharma, Loren Clarke, Klaus Helm, David Mauger, Gavin P Robertson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15482489     DOI： 10.1111/j.0022-202X.2004.23468.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  17 in total

1.  The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.

Authors:  Elke Stadelmeyer; Ellen Heitzer; Margit Resel; Lorenzo Cerroni; Peter Wolf; Nadia Dandachi
Journal:  J Invest Dermatol       Date:  2013-08-09       Impact factor: 8.551

2.  An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood.

Authors:  David J Panka; Ryan J Sullivan; James W Mier
Journal:  Melanoma Res       Date:  2010-10       Impact factor: 3.599

3.  Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Authors:  David J Panka; Elizabeth Buchbinder; Anita Giobbie-Hurder; Aislyn P Schalck; Laleh Montaser-Kouhsari; Alireza Sepehr; Donald P Lawrence; David F McDermott; Rachel Cohen; Alexander Carlson; Jennifer A Wargo; Ryan Merritt; Virginia J Seery; F Stephen Hodi; Anasuya Gunturi; Dennie Fredrick; Michael B Atkins; A John Iafrate; Keith T Flaherty; James W Mier; Ryan J Sullivan
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

4.  Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.

Authors:  Arati Sharma; Melissa A Tran; Shile Liang; Arun K Sharma; Shantu Amin; Charles D Smith; Cheng Dong; Gavin P Robertson
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

5.  PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.

Authors:  Panagiotis A Vorkas; Nikoleta Poumpouridou; Sophia Agelaki; Christos Kroupis; Vassilis Georgoulias; Evi S Lianidou
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

6.  Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma.

Authors:  Molly Yancovitz; Joanne Yoon; Maryann Mikhail; Weiming Gai; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Paul B Chapman; Iman Osman; David Polsky
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

7.  Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.

Authors:  Shile Liang; Arati Sharma; Hsin-Hsin Peng; Gavin Robertson; Cheng Dong
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

8.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 9.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

10.  Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

Authors:  Melissa A Tran; Raghavendra Gowda; Arati Sharma; Eun-Joo Park; James Adair; Mark Kester; Nadine Barrie Smith; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.